WUXI, China, June 5, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global CRDMO service company, announced it has successfully launched the GMP operation of its new drug product ...
(MENAFN- GlobeNewsWire - Nasdaq) This course offers market opportunities through comprehensive training on pre-filled syringe processing, featuring independent, vendor-neutral expertise and ...
WuXi Biologics, a CDMO, launched the GMP operation of its new drug product facility DP5 located in Wuxi, China. The DP5 is the ninth operational drug product facility in the global network of WuXi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results